Table of Contents
Introduction
The Global Veterinary Oncology Market is projected to reach approximately USD 5.1 billion by 2034, growing from USD 1.7 billion in 2024, at a compound annual growth rate (CAGR) of 11.7% during the forecast period. The rising demand for veterinary oncology services is being driven by several major factors. These include demographic shifts in pet populations, technological improvements in veterinary care, heightened pet owner awareness, regulatory support, and cross-benefits to human oncology research. Together, these dynamics are shaping the expansion and significance of veterinary oncology in the broader animal healthcare sector.
The steady increase in global pet ownership has expanded the demand for comprehensive veterinary services. As pets are living longer lives, age-related diseases, such as cancer, are becoming more prevalent. This demographic trend has created a growing need for specialized oncology treatments for companion animals. According to veterinary health experts, older pets are more prone to develop neoplasia, underscoring the need for early cancer detection and management. This shift is a key driver in boosting the adoption of oncology services across veterinary clinics and hospitals worldwide.
Significant technological advancements have transformed veterinary oncology practices. Innovations such as advanced imaging technologies, molecular diagnostics, and targeted therapies have improved both the accuracy of cancer detection and the effectiveness of treatments. These technologies have enhanced survival rates and quality of life for animals diagnosed with cancer. Furthermore, the World Health Organization (WHO) emphasizes that improvements in diagnostic capabilities are crucial for better health outcomes, reinforcing the importance of continued innovation in veterinary diagnostics and therapeutics.
Pet owners are becoming more informed about their animals’ health needs and are willing to invest more in their pets’ well-being. This cultural shift has led to higher spending on specialized healthcare, including oncology services. A growing number of pet insurance programs covering cancer treatments have also made advanced therapies more accessible. This increase in consumer willingness to seek specialized care has accelerated the expansion of veterinary oncology offerings, particularly in developed markets such as North America and Europe.
Governmental and health organizations have recognized the growing importance of veterinary oncology. The U.S. Food and Drug Administration (FDA) has issued guidance to encourage the development of oncology drugs for companion animals. Additionally, veterinary oncology research often supports human oncology through the field of comparative oncology. Insights gained from studying animal cancers are helping to advance human cancer therapies. This interconnected research strengthens the value of veterinary oncology and promotes collaboration across medical fields, supporting its sustained market growth.
Key Takeaways
- The global veterinary oncology market was valued at approximately US$ 1.7 billion in 2024 and is forecasted to reach US$ 5.1 billion by 2034.
- The market is expected to expand at a compound annual growth rate (CAGR) of 11.7% over the forecast period from 2024 to 2034.
- In 2024, the canine segment dominated the veterinary oncology market, capturing nearly 82% of the total revenue share worldwide.
- Immunotherapy emerged as the leading treatment segment in 2024, accounting for about 24% of the overall revenue generated globally.
- North America retained its dominance in the veterinary oncology market, holding a substantial share of over 53% of the total global revenue.
Emerging Trends
- Precision Diagnostics: Liquid Biopsy: Liquid biopsy is a non-invasive test that detects cancer-specific DNA fragments in pets through a simple blood sample. It allows for earlier cancer detection compared to traditional methods, often identifying tumors before any clinical signs appear. Early diagnosis improves the chances of successful treatment and better outcomes for pets. This method reduces the need for surgical biopsies, making it safer and less stressful for animals. As liquid biopsy technology advances, its use is becoming more common in veterinary practices. This trend reflects a major shift toward precision diagnostics in animal healthcare, improving both diagnosis speed and accuracy.
- Targeted Therapies: Targeted therapies are transforming cancer care for pets by focusing specifically on cancer cells while sparing healthy tissues. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted treatments cause fewer side effects. These therapies are now increasingly available for veterinary use, offering better results and a higher quality of life for pets undergoing cancer treatment. Drugs are designed based on the molecular profile of the tumor, allowing a more personalized approach. The expansion of targeted therapies marks a significant advance in veterinary oncology, providing pet owners with more effective and safer treatment options.
- Immunotherapy Integration: The combination of radiation therapy with immunotherapy is gaining attention in veterinary oncology. Radiation therapy can expose tumor-specific antigens, making cancer cells easier for the immune system to recognize and attack. This approach enhances the effectiveness of immunotherapies, especially in aggressive cancers like feline oral squamous cell carcinoma. Research is ongoing to optimize this combination therapy in pets. Early studies show promising results, with improved survival rates and fewer side effects. Integrating immunotherapy into standard veterinary cancer treatments could significantly reshape how cancers are managed in animals in the near future.
- Electrochemotherapy (ECT): Electrochemotherapy (ECT) is an innovative technique that uses electrical pulses to temporarily open cancer cell membranes. This process allows chemotherapy drugs to enter cancer cells more effectively. ECT has shown positive results in treating soft tissue sarcomas and mast cell tumors in pets. The procedure is minimally invasive, reduces the required chemotherapy dosage, and lowers systemic toxicity. It also improves the likelihood of complete tumor remission. Veterinarians are increasingly adopting ECT because of its effectiveness and safety profile. As awareness grows, electrochemotherapy is expected to become a standard option for treating specific types of tumors in pets.
- Comparative Oncology: Comparative oncology studies naturally occurring cancers in pets, mainly dogs, to advance cancer research for both animals and humans. Dogs develop cancers similar to those seen in humans, both genetically and biologically. Because of this, dogs serve as excellent models for testing new cancer therapies. Insights gained from treating canine cancers help in designing better treatments for human patients. Comparative oncology is bridging the gap between veterinary and human medicine, creating opportunities for faster drug development. This trend is enhancing collaboration between veterinary oncologists and human cancer researchers, ultimately improving care outcomes for both species.
Use Cases
- Early Detection of Canine Cancers: The OncoK9 liquid biopsy test is helping dogs by detecting cancers at an early stage. It shows an 85% accuracy rate in identifying aggressive cancers. Early detection means that veterinarians can begin treatment sooner. This greatly improves a dog’s chances of survival and can lead to better long-term health outcomes. Earlier intervention also reduces the severity of treatments needed. Owners benefit from having more options to support their pet’s health. By finding cancer early, dogs can live longer and healthier lives, making early detection a vital part of veterinary oncology.
- Treatment of Canine Lymphoma: Rabacfosadine, known as Tanovea-CA1, is the first FDA-approved injectable chemotherapy for dogs with lymphoma. It provides a targeted treatment option that is both effective and safe. Clinical studies have shown that Rabacfosadine can improve survival rates in dogs diagnosed with this disease. It also helps enhance the quality of life during treatment. The drug targets cancer cells directly, limiting damage to healthy cells. This advancement offers veterinarians a powerful tool in managing one of the most common cancers found in dogs. Pet owners now have a scientifically backed option to support their pets through cancer treatment.
- Management of Mast Cell Tumors: Tigilanol tiglate, marketed as Stelfonta, is an intratumoral therapy approved for treating non-metastatic cutaneous mast cell tumors in dogs. Clinical trials have reported a complete tumor resolution rate of up to 75%. This treatment involves a simple injection directly into the tumor site. It reduces the need for invasive surgery, leading to faster recovery and less discomfort for the animal. Veterinarians now have an alternative option for managing skin tumors, especially when surgery is not possible. Stelfonta has been a significant step forward in the non-surgical management of canine mast cell tumors.
- Advancements in Radiation Therapy: Mobile radiation therapy units are changing how cancer care is delivered to pets. These units make it possible to treat superficial tumors with precision, without needing a large, dedicated radiation facility. This advancement means that more veterinary clinics can offer radiation therapy services. It improves access to advanced cancer treatment for pets living in remote or underserved areas. Mobile units ensure that radiation therapy is delivered safely and effectively. This innovation is making high-quality cancer treatment more widely available, helping more pets to receive life-saving therapies without extensive travel.
- Comparative Oncology Trials: Comparative oncology trials are offering hope to both dogs and humans. Clinical trials studying osteosarcoma in dogs have provided important data for new treatment developments. Research in veterinary oncology has helped to discover therapies that are now being tested or used for human patients. These trials highlight the important role dogs play in advancing cancer treatments across species. Veterinarians and researchers work together to create therapies that can save lives. Comparative oncology bridges the gap between animal and human medicine, offering better treatments for all. It strengthens the value of veterinary research worldwide.
Conclusion
The veterinary oncology sector is experiencing steady growth, driven by rising pet ownership, longer pet lifespans, and major advances in cancer diagnostics and treatments. As pet owners become more aware of available options, demand for specialized oncology services is expanding rapidly. Technological innovations like liquid biopsy, targeted therapies, and electrochemotherapy are improving treatment success and quality of life for animals. Moreover, the collaboration between veterinary and human cancer research through comparative oncology is creating new opportunities for medical advancement. With strong support from regulatory bodies and growing investment in animal health, veterinary oncology is expected to continue playing a crucial role in the future of pet healthcare.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
